A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemot

A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer is a phase 2, interventional study registered as NCT07543848 by Chongqing University Cancer Hospital, with a registry enrolment figure of 20 participants, started 2026-05-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: Serplulimab; Oncolytic Virus H101; XELOX Chemotherapy; Short-course Radiotherapy. Conditions listed: Rectal Neoplasms; Rectal Adenocarcinoma. Primary outcome: 1-year Clinical Complete Response Rate. Colorectal eligibility wording from the registry: "Histologically confirmed low rectal adenocarcinoma, with tumor located ≤5 cm from the anal verge". Sites: China. No results are recorded here; the registry entry is the source.